"NUMBER NEEDED TO TREAT" ANALYSIS TO ASSESS THE COMPARATIVE OUTCOMES FROM TERIFLUNOMIDE AND DIMETHYL FUMARATE STUDIES IN RELAPSING MULTIPLE SCLEROSIS

被引：0
|
作者：
Leist, T. P. [1 ]
Montalban, X. [2 ]
Miller, A. E. [3 ]
Dive-Pouletty, C. [4 ]
Freedman, M. S. [5 ,6 ]
机构：
[1] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Genzyme, Chilly Mazarin, France
[5] Univ Ottawa, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Ottawa, ON, Canada
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND13
引用
收藏
页码：A279 / A280
页数：4
相关论文
共 50 条
  • [1] "Number Needed to Treat" analysis to assess the comparative outcomes from teriflunomide and dimethyl fumarate studies in relapsing multiple sclerosis
    Freedman, M. S.
    Montalban, X.
    Miller, A. E.
    Dive-Pouletty, C.
    Leist, T. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 443 - 443
  • [2] ASSESSING THE COMPARATIVE OUTCOMES FROM TERIFLUNOMIDE AND DIMETHYL FUMARATE STUDIES IN RELAPSING MS: USE OF "NUMBER NEEDED TO TREAT" ANALYSIS
    Freedman, M. S.
    Montalban, X.
    Miller, A. E.
    Dive-Pouletty, C.
    Leist, T. P.
    VALUE IN HEALTH, 2014, 17 (07) : A392 - A392
  • [3] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Mueller, J.
    Schaedelin, S.
    Benkert, P.
    Haenni, P.
    Schmid, J.
    Derfuss, T.
    Kuhle, J.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 676
  • [4] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Muller, Jannis
    Schadelin, Sabine
    Lorscheider, Johannes
    Benkert, Pascal
    Hanni, Peter
    Schmid, Jurg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Yaldizli, Ozgur
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818
  • [5] Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
    Freedman, Mark S.
    Montalban, Xavier
    Miller, Aaron E.
    Dive-Pouletty, Catherine
    Hass, Steven
    Thangavelu, Karthinathan
    Leist, Thomas P.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 10 : 204 - 212
  • [6] Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies
    Luca Prosperini
    Shalom Haggiag
    Serena Ruggieri
    Carla Tortorella
    Claudio Gasperini
    Neurotherapeutics, 2023, 20 : 1275 - 1283
  • [7] Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
    Laplaud, David-Axel
    Casey, Romain
    Barbin, Laetitia
    Debouverie, Marc
    De Seze, Jerome
    Brassat, David
    Wiertlewski, Sandrine
    Brochet, Bruno
    Pelletier, Jean
    Vermersch, Patrick
    Edan, Gilles
    Lebrun-Frenay, Christine
    Clavelou, Pierre
    Thouvenot, Eric
    Camdessanche, Jean-Philippe
    Tourbah, Ayman
    Stankoff, Bruno
    Al Khedr, Abdullatif
    Cabre, Philippe
    Lubetzki, Catherine
    Papeix, Caroline
    Berger, Eric
    Heinzlef, Olivier
    Debroucker, Thomas
    Moreau, Thibault
    Gout, Olivier
    Bourre, Bertrand
    Wahab, Abir
    Labauge, Pierre
    Magy, Laurent
    Defer, Gilles
    Guennoc, Anne-Marie
    Maubeuge, Nicolas
    Labeyrie, Celine
    Patry, Ivania
    Nifle, Chantal
    Casez, Olivier
    Michel, Laure
    Rollot, Fabien
    Leray, Emmanuelle
    Vukusic, Sandra
    Foucher, Yohann
    Fontaine, B.
    Marignier, R.
    Durand-Dubief, F.
    Mathey, G.
    Le Page, E.
    Peaureaux-Averseng, D.
    Ouallet, J. C.
    Ruet, A.
    NEUROLOGY, 2019, 93 (07) : E635 - E646
  • [8] Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study
    Kalincik, T.
    Spelman, T.
    Jokubaitis, V.
    Horakova, D.
    Havrdova, E.
    Izquierdo, G.
    Prat, A.
    Girard, M.
    Duquette, P.
    Lugaresi, A.
    Grammond, P.
    Alroughani, R.
    Lechner-Scott, J.
    Prevost, J.
    Terzi, M.
    Grand'Maison, F.
    Boz, C.
    Trojano, M.
    Van Wijmeersch, B.
    Pucci, E.
    Granella, F.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    McCombe, P.
    Solaro, C.
    Van Pesch, V.
    Ozakbas, S.
    Slee, M.
    Spitaleri, D.
    Sanchez-Menoyo, J. L.
    Ampapa, R.
    Hodgkinson, S.
    Karabudak, R.
    Vucic, S.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 325 - 327
  • [9] Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
    Johannes Lorscheider
    Pascal Benkert
    Carmen Lienert
    Peter Hänni
    Tobias Derfuss
    Jens Kuhle
    Ludwig Kappos
    Özgür Yaldizli
    Journal of Neurology, 2021, 268 : 941 - 949
  • [10] Number needed to treat analysis comparing teriflunomide with injectable and oral disease-modifying therapies in relapsing multiple sclerosis
    Freedman, M. S.
    Miller, A. E.
    Thangavelu, K.
    Hass, S.
    Leist, T. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 668 - 668
12345